SCHEDULE: Invus Group Entities Disclose 9.4% Stake in Nanobiotix

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 9.4% of Nanobiotix S.A.'s ordinary shares, including shares issuable from warrants.

Summary

• Invus Public Equities, L.P. and its associated entities (Invus PE Advisors, Global Management, Siren, and Raymond Debbane) have disclosed a beneficial ownership of 4,828,374 ordinary shares of Nanobiotix S.A.
• This represents 9.4% of the total outstanding ordinary shares as of May 31, 2026, plus shares issuable from warrants.
• The filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership or a periodic update.
• The reporting persons state that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not overwhelming stake in Nanobiotix S.A. by Invus entities. The disclosure itself is routine for significant shareholders.

Positives

• Significant investment by Invus entities indicates confidence in Nanobiotix's long-term prospects.
• The stake of 9.4% is substantial, suggesting a notable level of commitment.
• The inclusion of pre-funded warrants in the beneficial ownership calculation indicates a potential for further investment.

Negatives

• The filing does not provide specific details on the investment strategy or future intentions beyond stating it's not for control.
• The total number of shares outstanding used for calculation (50,807,903) is based on a filing from May 31, 2026, and may not reflect the most current outstanding share count.

Risks

• Potential for future share sales by Invus entities could impact Nanobiotix's stock price.
• The exercise of warrants could lead to dilution if not managed carefully by the company.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Nanobiotix S.A. It primarily reports on the beneficial ownership of securities by the Invus entities.

Management Comments

• Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner, signed the certification stating that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment firms accumulating significant stakes in publicly traded companies. This filing indicates a substantial investment by the Invus Group in Nanobiotix, a biotechnology company focused on cancer treatments, aligning with broader investment trends in the healthcare and biotech sectors.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by Invus entities may be viewed positively, potentially signaling confidence in the company's future. However, future trading activity by Invus could impact share price.
• Management: The filing confirms that the investment is not intended to influence control, which may provide some stability.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• Invus entities will continue to hold or potentially adjust their stake in Nanobiotix S.A.
• Nanobiotix S.A. will continue its operations and business development activities.

Key Dates

Keywords

Nanobiotix, Schedule 13G, Invus Public Equities, Beneficial Ownership, Ordinary Shares, Warrants, Investment Disclosure, Raymond Debbane